Blue Earth Diagnostics
Unit F14, The Oxford Science Park
Magdalen Centre, Robert Robinson Avenue
Oxford
OX4 4GA
United Kingdom
Tel: 44-0-1865-784-186
Fax: 44-0-1865-784-004
Website: http://www.blueearthdiagnostics.com/
Email: contact@blueearthDx.com
79 articles with Blue Earth Diagnostics
-
Blue Earth Diagnostics Announces Additional Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer
2/16/2023
Blue Earth Diagnostics announced additional results from its Phase 3 LIGHTHOUSE trial that evaluated the diagnostic performance and safety of 18F-rhPSMA-7.3 in newly diagnosed prostate cancer.
-
Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 LIGHTHOUSE Study of 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer
2/9/2023
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced the presentation of additional results from its completed Phase 3 LIGHTHOUSE trial of 18F-rhPSMA-7.3 in newly diagnosed prostate cancer, at the upcoming ASCO GU 2023 Genitourinary Cancers Symposium (ASCO GU).
-
Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer
12/1/2022
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced topline results from its Phase 3 LIGHTHOUSE trial that evaluated the diagnostic performance and safety of 18F-rhPSMA-7.3 in newly diagnosed prostate cancer.
-
Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) at Upcoming RSNA® 2022 Annual Meeting
11/22/2022
Blue Earth Diagnostics Highlights Presentations on Axumin ® (Fluciclovine F 18) at Upcoming RSNA ® 2022 Annual Meeting.
-
Blue Earth Diagnostics Highlights Upcoming Presentation of Results from Phase 3 LIGHTHOUSE Study of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer
11/21/2022
Blue Earth Diagnostics today announced presentations on investigational rhPSMA compounds and Axumin® (fluciclovine F 18) at the upcoming 23rd Annual Scientific Meeting in Urologic Oncology (SUO), to be held in San Diego, Calif., from November 30 to December 2, 2022.
-
Blue Earth Diagnostics Announces Results on Clinical Factors Impacting Detection Rates from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer
10/24/2022
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced results from its Phase 3 SPOTLIGHT trial that evaluated the impact of various clinical factors, including baseline Prostate Specific Antigen (PSA) levels, PSA doubling time and Gleason score, on detection rates (DRs) for 18F-rhPSMA-7.3 in recurrent prostate cancer.
-
Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) and Investigational 18F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer at Upcoming ASTRO Annual Meeting
10/19/2022
Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) and Investigational 18 F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer at Upcoming ASTRO Annual Meeting.
-
Blue Earth Diagnostics Announces Data-sharing Agreement with Siemens Healthineers and the University Hospital of Technical University of Munich (TUM) for 18F-rhPSMA-7.3
10/18/2022
Blue Earth Diagnostics today announced the signing of a data-sharing agreement with Siemens Healthineers and the University Hospital of the Technical University of Munich (TUM) for anonymized 18 F-rhPSMA-7.3 clinical data and images.
-
The FDA had a busy week, approving drugs, greenlighting clinical trials and other regulatory activities for Immuneering, Amylyx, Sarepta, Sanofi, and Regeneron and more.
-
Blue Earth Diagnostics Announces FDA Acceptance of New Drug Application for 18F-rhPSMA-7.3, a Radiohybrid Prostate-Specific Membrane Antigen-Targeted PET Imaging Agent for Prostate Cancer
9/27/2022
Blue Earth Diagnostics Announces FDA Acceptance of New Drug Application for 18 F-rhPSMA-7.3, a Radiohybrid Prostate-Specific Membrane Antigen-Targeted PET Imaging Agent for Prostate Cancer.
-
Independent Clinical Studies Published Regarding Performance of Axumin® (Fluciclovine F 18) PET Imaging in Patients with Recurrent Prostate Cancer Undergoing Androgen Deprivation Therapy (ADT)
7/19/2022
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today shared news of the publication of two independent, retrospective studies evaluating the use of Axumin® (fluciclovine F 18) PET imaging in men with biochemical recurrence of prostate cancer who were undergoing androgen deprivation therapy (ADT).
-
Blue Earth Diagnostics Announces Reader Reproducibility Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer
6/15/2022
Blue Earth Diagnostics Announces Reader Reproducibility Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18 F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer.
-
Blue Earth Diagnostics Highlights Presentations on Investigational rhPSMA Radiopharmaceuticals and 18F-Fluciclovine at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
6/9/2022
Blue Earth Diagnostics Highlights Presentations on Investigational rhPSMA Radiopharmaceuticals and 18 F-Fluciclovine at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
-
Blue Earth Diagnostics Completes Patient Accrual in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases
6/8/2022
Blue Earth Diagnostics Completes Patient Accrual in Phase 3 REVELATE Clinical Trial of 18 F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases.
-
Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer
5/13/2022
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced results of additional endpoints from its Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 in recurrent prostate cancer.
-
Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Phase 3 SPOTLIGHT Study of Targeted PET Imaging Agent 18F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer
5/5/2022
Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Phase 3 SPOTLIGHT Study of Targeted PET Imaging Agent 18 F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer.
-
Blue Earth Diagnostics Appoints Dr. David E. Gauden as Chief Executive Officer and Dr. Eugene J. Teoh as Chief Medical Officer
2/28/2022
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced the appointment of David E. Gauden, D.Phil. as its new Chief Executive Officer (CEO).
-
Blue Earth Diagnostics Announces Key Results from Phase 3 SPOTLIGHT Study of 18F-rhPSMA-7.3, an Investigational PET Imaging Agent, in Biochemical Recurrence of Prostate Cancer
2/15/2022
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced publication of key results from its Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 in recurrent prostate cancer in an abstract being presented at the ASCO 2022 Genitourinary Cancers Symposium (ASCO GU).
-
Blue Earth Diagnostics Highlights Upcoming Presentation of Key Results from Phase 3 SPOTLIGHT Study of Targeted PET Imaging Agent 18F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer
2/1/2022
Blue Earth Diagnostics Highlights Upcoming Presentation of Key Results from Phase 3 SPOTLIGHT Study of Targeted PET Imaging Agent 18 F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer.
-
Blue Earth Diagnostics Highlights Axumin® (Fluciclovine F 18) Presentation at Upcoming 22nd Annual Scientific Meeting in Urologic Oncology (SUO)
11/30/2021
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, announced a presentation on Axumin® at the upcoming 22nd Annual Scientific Meeting in Urologic Oncology, to be held in Orlando, Fla., from December 1 to 3, 2021.